dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de São Paulo (USP)
dc.contributorInstituto Adolfo Lutz (IAL)
dc.date.accessioned2014-05-20T13:24:31Z
dc.date.available2014-05-20T13:24:31Z
dc.date.created2014-05-20T13:24:31Z
dc.date.issued2007-12-01
dc.identifierTropical Journal of Pharmaceutical Research. Benin City: Pharmacotherapy Group, v. 6, n. 4, p. 815-824, 2007.
dc.identifier1596-5996
dc.identifierhttp://hdl.handle.net/11449/7634
dc.identifier10.4314%2Ftjpr.v6i4.14665
dc.identifierWOS:000253261500004
dc.identifierWOS000253261500004.pdf
dc.identifier2114570774349859
dc.description.abstractPurpose: This paper focuses on the characterization of polymeric micelle-forming tuberculostatic prodrugs and the antimycobacterial activity of these prodrugs.Method: By the condensation of hydroxymethylpyrazinamide, isoniazid and rifampin with free carboxyl groups on the copolymer poly(ethyleneglycol)-poly(aspartic acid), micelle-forming carrier-drug conjugates were obtained. These micelles were characterized by dynamic light scattering, to measure the micelle diameter; by acid-base titration, to determine the percentage of carboxylic groups occupied by the tuberculostatic; by Sudan III solubility tests, to estimate the critical micelle concentration (CMC); and visual control and spectrophotometric measurement, to determine the stability of micelles. These micelles were tested in vitro against several Mycobacterium strains.Results: As expected, the size and distribution of the micelle-forming tuberculostatic prodrugs found to be small (78.2nm, 84.2nm and 98.9 nm) while the level of the drug conjugated was high (65.02-85.7%). Furthermore, the micelles were stable in vitro, exhibiting a low level of CMC and stronger antimycobacterial activity than the original drugs.Conclusion: the results demonstrate that polymeric micelles can be used as efficient carriers for drugs, which alone, exhibit undesired pharmacokinetics, poor solubility, and low stability. The synthesized micelle-forming tuberculostatic prodrugs opens a perspective of alternative prodrugs that prolong action and decrease the toxicity of the tuberculostatic drugs of choice.
dc.languageeng
dc.publisherPharmacotherapy Group
dc.relationTropical Journal of Pharmaceutical Research
dc.relation0.444
dc.relation0,256
dc.rightsAcesso aberto
dc.sourceWeb of Science
dc.subjectpyrazinamide
dc.subjectisoniazid
dc.subjectrifampin
dc.subjecttuberculostatic prodrugs
dc.subjectpolymer micelles
dc.titlePreparation of polymeric micelles for use as carriers of tuberculostatic drugs
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución